AI-generated · cited to primary sources · not investment advice
Moderna, Inc. (MRNA) Sep 2025 Filing Analysis
Does management do what it says?
RSV sales remained immaterial relative to total product sales through nine months, consistent with management's expectation. (3 met across 3 tracked commitments)
“Although we commenced sales of our RSV vaccine in the third quarter of 2024, product sales from our RSV vaccine are not expected to present a significant portion of total product sales in 2025.”
The filing confirms that COVID vaccine demand declined through 2025, consistent with management's prior expectation. The filing does not provide the full-year 2025 net product-sales comparison versus 2024, so the magnitude of the decline cannot be independently quantified here. (2 met across 2 tracked commitments)
“We expect demand for our COVID and RSV vaccines to follow a seasonal pattern aligned with fall and winter vaccination campaigns in both hemispheres.”
The expected full-year decline remains supported by year-to-date performance and management commentary, but the full-year result is not yet available. Nine-month net product sales were down 46% year over year, and third-quarter sales were down 47%, primarily because of lower COVID vaccine sales. (1 in progress across 1 tracked commitment)
“We expect demand for our COVID and RSV vaccines to follow a seasonal pattern aligned with fall and winter vaccination campaigns in both hemispheres. As COVID has transitioned to a seasonal respiratory vaccine, we anticipate a decline in net product sales for the full year 2025 compared to 2024, primarily due to lower expected vaccination rates and a more competitive commercial market environment.”
Nine-month cost of sales declined materially year over year, and management reaffirmed the full-year decline expectation. Full-year delivery is not yet observable. (2 in progress, 1 not yet due across 3 tracked commitments)
“We expect full year 2025 cost of sales to be lower compared to 2024, primarily driven by a reduction in period charges, particularly lower wind-down costs related to contract manufacturing organization contracts and inventory write-downs, along with lower anticipated sales volume.”
Management expects continued negative operating cash flow in upcoming periods while investing in future product launches, clinical development, commercial infrastructure, and manufacturing facilities. (+1 more commitment)
“We foresee that our commitment to investing in our business for future product launches may lead to continued negative cash flows from operations in upcoming periods.”
See the full cited Management analysis of Moderna, Inc.
What could break the thesis?
The risk remained high, although some individual charges improved year over year. Inventory increased from $117 million to $332 million, including $128 million of finished goods, and total vaccine inventory on hand was $447 million. Nine-month inventory write-downs declined from $302 million to $147 million, but remained significant; the company also recorded $24 million of losses on firm purchase commitments and $50 million of unused-capacity and manufacturing wind-down costs. Management said fixed manufacturing costs could not be quickly adjusted when demand falls and that cost of sales as a percentage of sales could vary widely. The improvement in write-downs was outweighed by continued demand uncertainty and large inventory exposure. The Jun 2026 baseline later reported further inventory write-downs, so the risk was not resolved. (2 stable, 1 easing, 1 intensifying)
“Cost of sales for the nine months ended September 30, 2025 ... included ... inventory write-downs of $147 million ... unutilized manufacturing capacity and wind-down costs of $50 million, and losses on firm purchase commitments of $24 million. ... cost of sales as a percentage of net product sales is expected to vary widely due to continued uncertainty around demand ... fixed nature of a significant portion of our manufacturing costs.”
See the full cited Risk analysis of Moderna, Inc.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.